4,005
Participants
Start Date
February 28, 2013
Primary Completion Date
November 30, 2013
Study Completion Date
June 30, 2014
IMVAMUNE®
0.5 ml IMVAMUNE® vaccine containing at least 1 x 10E8 TCID50 (standard dose)
Placebo
0.5 ml TBS
Rochester Clinical Research, Inc., Rochester
Clinical Research Associates of Tidewater, Norfolk
University Physicians Internal Medicine University Physicians & Surgeons, Inc., Huntington
Wake Research Associates, Raleigh
PMG Research of Charleston, Mt. Pleasant
Southeast Regional Research Group, Savannah
Avail Clinical Research, LLC, DeLand
Accelovance Melbourne, Melbourne
Broward Research Group, Hollywood
Alabama Vaccine Research Clinic, Birmingham
Holston Medical Group, Bristol
Volunteer Research Group, Knoxville
Rapid Medical Research, Inc., Cleveland
Family Practice Center of Wooster, Wooster
Accelovance Peoria, Peoria
Washington University in St. Louis, School of Medicine, St Louis
QPS Bio-Kinetic, Springfield
Heartland Research Associates, Augusta
Heartland Research Associates, LLC, Wichita
Meridian Clinical Research, LLC, Omaha
Benchmark Research, Metairie
Lynn Health Science Institute, Oklahoma City
Benchmark Research, Fort Worth
Lynn Institute of the Rockies, Colorado Springs
Advanced Clinical Research, Inc., Meridian
Tanner Clinic, Layton
Advanced Clinical Research, West Jordan
Clinical Research Center of Nevada, LLC, Las Vegas
National Research Institute, Los Angeles
Therapeutics Clinical Research, San Diego
Anaheim Clinical Trials, Anaheim
Northern California Clinical Research Center (NCCRC), Redding
Columbia Research Group, Inc., Portland
Omega Medical Research, Warwick
Lead Sponsor
Bavarian Nordic
INDUSTRY